RxDoctor Payments Data

Blake Hatfield, MD

Internal Medicine · Dallas, TXNPI 1811382062

Payments from drug & device makers

$1,530in general payments, 2019–2025

Across 82 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$387
  • Merck$288
  • AbbVie$262
  • Viiv Healthcare Company$113
  • Johnson & Johnson$65
  • Lilly USA, LLC$63
  • plus $352 from 11 others

What the payments were for

  • Food & beverage$1,530100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,530 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$103,261
Medicare patients
248
Services billed
1,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala319$1,401,489
TriumeqAbacavir/Dolutegravir/Lamivudi215$843,613
DescovyEmtricitabine/Tenofov Alafenam294$718,517
PrezcobixDarunavir/Cobicistat136$348,388
TivicayDolutegravir Sodium137$301,399
GenvoyaElviteg/Cob/Emtri/Tenof Alafen44$249,112
Egrifta SvTesamorelin Acetate29$241,608
MounjaroTirzepatide107$136,720
IsentressRaltegravir Potassium56$135,796
DovatoDolutegravir Sodium/Lamivudine39$112,426
OdefseyEmtricitab/Rilpiviri/Tenof Ala24$89,673
OzempicSemaglutide67$87,017
CabenuvaCabotegravir/Rilpivirine13$82,958
TrulicityDulaglutide46$72,173
EdurantRilpivirine Hcl30$43,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$387$2,369,118657 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Cabenuva$113$1,340,396404 claims
Johnson & JohnsonPrezcobix, Xarelto$65$369,549155 claims
Theratechnologies Inc.Egrifta Sv$17$241,60829 claims
Lilly USA, LLCMounjaro, Trulicity$63$208,893153 claims
MerckIsentress$288$135,79656 claims
Novo NordiskOzempic, Rybelsus$58$98,32579 claims
PfizerEliquis$58$34,21731 claims
Astellas Pharma US IncMyrbetriq$15$14,43411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →